Literature DB >> 8154927

Influence of various cytokines on the interleukin-2-dependent lysis of melanoma cells in vitro.

E S Schultz1, R Dummer, J C Becker, D Zillikens, G Burg.   

Abstract

To obtain information about useful combinations of various cytokines in melanoma therapy, we studied the influence of interleukin-2 (IL-2) in combination with interferon-alpha (IFN-alpha), IFN-gamma and tumour necrosis factor-alpha (TNF-alpha) on the lytic activity of IL-2-stimulated cells in vitro. Peripheral mononuclear cells (PMC) were incubated for 4 days with various combinations of cytokines and used as effector cells. Two different melanoma cell lines (M19 and M26) were used as target cells. The lytic activity of stimulated PMC was determined using a modified hexosaminidase assay. IL-2 was mainly responsible for the lytic activity of the effector cells in a dose-dependent manner. IFN-alpha, IFN-gamma and TNF-alpha did not enhance lytic activity with an optimal IL-2 dose (50 IU/ml IL-2). Using a suboptimal IL-2 dose (5 IU/ml), they increased cytotoxicity. The specific lysis of M19 cells was significantly increased by pretreatment of the cells with 5 IU/ml IFN-alpha together with 50 IU/ml TNF-alpha (t-test, P < or = 0.001), while the specific lysis of M26 cells was increased by pretreatment with 5 IU/ml IFN-gamma. We conclude that the lysis of melanoma cells by cytotoxic cells in vitro can be enhanced by various cytokines. The optimal cytokine combination differed for the two melanoma cell lines tested.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8154927     DOI: 10.1007/bf00370730

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  21 in total

Review 1.  NK cells and T cells: mirror images?

Authors:  R Versteeg
Journal:  Immunol Today       Date:  1992-07

2.  Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.

Authors:  S A Rosenberg; M T Lotze; J C Yang; P M Aebersold; W M Linehan; C A Seipp; D E White
Journal:  Ann Surg       Date:  1989-10       Impact factor: 12.969

3.  Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy.

Authors:  M Hirsh; A Lipton; H Harvey; E Givant; K Hopper; G Jones; J Zeffren; D Levitt
Journal:  J Clin Oncol       Date:  1990-10       Impact factor: 44.544

Review 4.  Interferon therapy of metastatic renal cell cancer.

Authors:  H B Muss
Journal:  Semin Surg Oncol       Date:  1988

5.  Lymphokine-activated killer (LAK) cells: interferon-gamma synergizes with interleukin-2 to induce LAK cytotoxicity in homogeneous leukemic preparations.

Authors:  Y Kaufmann; J Davidsohn; M Levanon; I Icekson; M Revel; B Ramot
Journal:  Clin Immunol Immunopathol       Date:  1991-02

6.  Cancer therapy with interleukin-2: immunologic manipulations can mediate the regression of cancer in humans.

Authors:  S A Rosenberg
Journal:  J Clin Oncol       Date:  1988-03       Impact factor: 44.544

7.  Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies.

Authors:  J Atzpodien; A Körfer; C R Franks; H Poliwoda; H Kirchner
Journal:  Lancet       Date:  1990-06-23       Impact factor: 79.321

8.  Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.

Authors:  S A Rosenberg; M T Lotze; J C Yang; W M Linehan; C Seipp; S Calabro; S E Karp; R M Sherry; S Steinberg; D E White
Journal:  J Clin Oncol       Date:  1989-12       Impact factor: 44.544

9.  Tumor necrosis factor alpha: a costimulator for cytotoxic cell differentiation.

Authors:  S Chouaib
Journal:  Nouv Rev Fr Hematol       Date:  1991

10.  Tumour necrosis factor-alpha enhances the cytolytic and cytostatic capacity of interleukin-2 activated killer cells.

Authors:  A Matossian-Rogers; C Browne; M Turkish; P O'Byrne; H Festenstein
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.